Question-and-Answer SessionSo before we kick it off, why don't you make some opening remarks in terms of just the progress over the last several years and importantly, what has happened this year, some of the accomplishments? And then how you're thinking about 2026?Benjamin HalladayChief Financial Officer Yes. There's a lot to unpack with that question. I'll do my best to keep it minimal. So I'll go back to April of 2024 when we received our cardiovascular outcomes trial updated label, which really kind of ...

ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Therape ...

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks another impor ...

Summary of Esperion Therapeutics Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Focus**: Development and commercialization of bempedoic acid, a cardiovascular drug Key Points Industry and Market Dynamics - **Market Expansion**: The addressable market for bempedoic acid increased from approximately 10 million patients to 70 million following the updated cardiovascular outcomes trial label in April 2024 [3][4] - **Growth Metrics**: Esperion has demonstrated double-digit growth quarter over quarter since the label update [3][4] - **Payer Landscape**: Major payers have improved reimbursement conditions, transitioning the drug from a niche product to a broadly labeled cardiovascular drug [3][4] Financial Performance and Strategy - **Debt Management**: Esperion has successfully reduced its debt, ending the year with less debt than it started [4][5] - **Profitability Goals**: The company aims to achieve sustainable profitability in Q1 2026, with expectations of generating substantial cash flow [26][45] Product and Pipeline Developments - **Guidelines Update**: Anticipated updates to U.S. guidelines in early 2026 are expected to align closely with European guidelines, which have already provided a strong recommendation for bempedoic acid [9][10] - **Market Access**: The company has improved market access, with high approval rates for prior authorizations, indicating strong positioning for bempedoic acid [14][15] - **Sales Strategy**: The sales force currently consists of 155 representatives, with plans to expand to capitalize on upcoming guidelines and market opportunities [19][25] Competitive Landscape - **Market Positioning**: Esperion believes it is well-positioned against competitors, with a strong outcomes trial and favorable payer access [29][30] - **Emerging Therapies**: The company is monitoring new oral therapies but does not feel significantly threatened by them due to its established market presence and outcomes data [30][31] Future Opportunities - **Expansion into Rare Diseases**: Esperion is exploring opportunities in rare diseases, with a focus on developing new compounds beyond lipid-lowering therapies [36][42] - **Cash Position**: The company reported a pro forma cash position of approximately $170 million, indicating strong financial health to support its initiatives [45] Conclusion - Esperion Therapeutics is on a growth trajectory with significant market potential for bempedoic acid, a solid financial foundation, and a strategic focus on expanding its product pipeline into rare diseases while maintaining its core cardiovascular offerings. The upcoming guidelines and market access improvements are expected to drive further growth and profitability.

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - The event focuses on addressing the issue of statin intolerance and aims to close the care gap in cardiovascular health [2][4]. Group 1: Event Overview - The conference is hosted by Esperion, featuring key opinion leaders discussing the challenges and solutions related to statin intolerance [1][2]. - The agenda includes an introduction, a segment on treatment barriers, and a Q&A session with medical experts [3][4]. Group 2: Key Speakers - Notable speakers include Dr. Fatima Rodriguez, Dr. Dharmesh Patel, and LeAnne Bloedon, who will present insights on the topic [3].

Summary of Esperion Therapeutics Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Event**: Key opinion leader-investor event focused on statin intolerance and cardiovascular health - **Date**: November 11, 2025 Key Points Financial Performance - **Q3 Total Revenue**: $87.3 million, representing a nearly 70% year-on-year growth [3] - **Q3 US Net Product Sales**: $40.7 million, indicating a 31% year-on-year growth [3] - **Retail Prescription Equivalents**: 9% increase quarter-over-quarter [4] Product Development and Market Position - **Nexletol and Nexlizet**: Outpacing the broader lipid-lowering market and exceeding growth of other non-statin therapies [4] - **Statin Intolerance**: Approximately 50% of patients starting statin therapy discontinue or have significant gaps in treatment within two years, highlighting a market opportunity for Nexletol and Nexlizet [5] - **Direct-to-Consumer Advertising**: Launched on platforms like Disney+ and Hulu, achieving over 6 million impressions since October [7] Clinical Insights - **Statin Intolerance Definition**: Up to 30% of US adults experience some degree of statin intolerance, which can lead to non-adherence and increased cardiovascular risk [10][12] - **Bempedoic Acid**: Developed to address statin intolerance, it is a pro-drug that targets the liver, avoiding muscle-related side effects associated with statins [15] - **Clinical Trials**: Bempedoic acid has shown significant LDL cholesterol reduction and hsCRP lowering, with the Clear Outcomes trial being the only outcomes study in statin-intolerant patients [19][22] Market Access and Awareness - **Medicare and Commercial Approval Rates**: 87% for Medicare and 86% for commercial plans, indicating improved access for patients [8] - **Patient Copays**: Average copays are $29 and $36 for a 30-day supply, reflecting growing payer confidence [8] - **Awareness Challenges**: There is a significant gap in awareness among healthcare professionals regarding non-statin therapies, which affects adoption rates [52][56] Physician Perspectives - **Patient Characteristics**: Females and older individuals are at higher risk for statin intolerance, and many patients are unwilling to start statin therapy due to perceived side effects [12][14] - **Combination Therapy**: There is a growing trend towards using combination therapies to achieve LDL targets, especially in high-risk patients [40][41] - **Imaging Tools**: Physicians are increasingly using imaging to educate patients about their cardiovascular risk and the importance of LDL-lowering therapies [48] Future Outlook - **Guideline Updates**: Recent ESC guidelines emphasize the importance of non-statin therapies, with bempedoic acid receiving high recommendations for statin-intolerant patients [22] - **Educational Commitment**: Esperion is dedicated to educating both healthcare providers and patients about statin intolerance and available alternatives [23] Additional Insights - **Patient Education**: There is a need for better education regarding the risks of high LDL cholesterol and the importance of treatment adherence [56] - **Market Potential**: The potential market for bempedoic acid is significant, especially among primary care populations and patients with diabetes [58] This summary encapsulates the key insights and data presented during the conference call, highlighting Esperion Therapeutics' performance, product positioning, and the broader implications for cardiovascular health management.

Virtual KOL Investor Event November 11, 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures Breaking the Statin Intolerance Barrier: Closing the Care Gap in Cardiovascular Health This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, expected profi ...

Core Insights - Esperion presented two post hoc analyses from the CLEAR Outcomes trial, highlighting the efficacy of bempedoic acid in reducing major adverse cardiovascular events (MACE-4) and venous thromboembolism (VTE) in patients not receiving other lipid-lowering therapies [1][2][3] Group 1: Efficacy of Bempedoic Acid - Bempedoic acid alone reduced MACE-4 by 14% compared to placebo in approximately 8,200 patients not on background lipid-lowering therapies [1][8] - The drug lowered LDL cholesterol by 20.6% at 6 months [8] - Patients treated with bempedoic acid were 42% less likely to experience VTE events compared to those on placebo, with a 44% reduction in deep venous thrombosis and a 39% reduction in pulmonary embolism [1][8] Group 2: Clinical Significance - The analyses reinforce the clinical value of NEXLETOL as a foundational therapy for cardiovascular risk reduction, especially for patients intolerant to statins [3] - The consistency of benefits from bempedoic acid monotherapy in lowering LDL-C and reducing MACE underscores its potential in preventive cardiology [3] Group 3: Presentation and Context - The data were presented at the 2025 American Heart Association Scientific Sessions, a significant forum in cardiovascular medicine [1][3] - Over half (59%) of the 13,970 participants in the CLEAR Outcomes trial were not receiving any background lipid-lowering therapy during the study [8]

Esperion Therapeutics, Inc. ( ESPR ) continues to execute under a cloud of market skepticism. While the stock has made an impressive recovery from the depths of skepticism in April and May, ESPR remains capped by important technical levelsDr. Duru has blogged about financial markets since the year 2000. A veteran of the dot-com bubble and bust, the financial crisis, and the coronavirus pandemic, he fully appreciates the value in trading and investing around the extremes of market behavior. In this spirit, h ...